VTE, ATE, or mortality: multivariable analysis
Predictor . | OR . | 95% CI . | P* . |
---|---|---|---|
Age >75 y | 3.66 | 2.84-4.71 | <.0001 |
BMI >35 kg/m2 | 0.95 | 0.73-1.24 | .691 |
Black race† | 0.79 | 0.57-1.09 | .149 |
Asian race† | 1.18 | 0.75-1.84 | .476 |
Other race† | 0.68 | 0.50-0.93 | .015 |
IMPROVE-DD ≥4 | 1.51 | 1.06-2.14 | .023 |
Anticoagulants (discharge) | 0.54 | 0.47-0.81 | .003 |
Antiplatelets (discharge) | 1.50 | 0.77-2.90 | .231 |
D-dimer 4-6× ULN‡ | 1.17 | 0.74-1.85 | .507 |
D-dimer >6× ULN‡ | 1.09 | 0.81-1.45 | .577 |
Personal history of VTE | 2.99 | 2.00-4.47 | <.0001 |
Coronary artery disease | 1.50 | 1.04-2.17 | .032 |
Peripheral arterial disease history | 2.04 | 1.10-3.80 | .024 |
Carotid occlusive disease history | 2.02 | 1.30-3.14 | .0002 |
Heart failure | 0.93 | 0.58-1.51 | .787 |
Chronic renal disease | 2.10 | 1.47-3.0 | <.0001 |
ICU admission | 2.22 | 1.78-2.93 | <.0001 |
Lymphocyte count | 0.97 | 0.96-0.99 | <.0001 |
Predictor . | OR . | 95% CI . | P* . |
---|---|---|---|
Age >75 y | 3.66 | 2.84-4.71 | <.0001 |
BMI >35 kg/m2 | 0.95 | 0.73-1.24 | .691 |
Black race† | 0.79 | 0.57-1.09 | .149 |
Asian race† | 1.18 | 0.75-1.84 | .476 |
Other race† | 0.68 | 0.50-0.93 | .015 |
IMPROVE-DD ≥4 | 1.51 | 1.06-2.14 | .023 |
Anticoagulants (discharge) | 0.54 | 0.47-0.81 | .003 |
Antiplatelets (discharge) | 1.50 | 0.77-2.90 | .231 |
D-dimer 4-6× ULN‡ | 1.17 | 0.74-1.85 | .507 |
D-dimer >6× ULN‡ | 1.09 | 0.81-1.45 | .577 |
Personal history of VTE | 2.99 | 2.00-4.47 | <.0001 |
Coronary artery disease | 1.50 | 1.04-2.17 | .032 |
Peripheral arterial disease history | 2.04 | 1.10-3.80 | .024 |
Carotid occlusive disease history | 2.02 | 1.30-3.14 | .0002 |
Heart failure | 0.93 | 0.58-1.51 | .787 |
Chronic renal disease | 2.10 | 1.47-3.0 | <.0001 |
ICU admission | 2.22 | 1.78-2.93 | <.0001 |
Lymphocyte count | 0.97 | 0.96-0.99 | <.0001 |